ViroPharma has posted a net income of $38.34m for the third quarter 2010, or $0.45 per diluted share, compared to $20.07m, or $0.24 per diluted share, for the comparable period in 2009.
Operating income was $59.24m, compared to $32.43m for the comparable period in 2009.
For the nine months ended 30 September 2010, ViroPharma has posted net product sales of $317.39m, compared to $222.61m for the year ago period.
For the nine months ended 30 September 2010, ViroPharma has posted a net income of $88.14m, or $1.04 per diluted share, compared to net loss of $23.09m, or $0.3 loss per diluted share, for the year ago period.
Operating income was $150.74m, compared to operating loss of $3.48m for the year ago period.
ViroPharma CEO Vincent Milano said that the third quarter of 2010 marked another consecutive period of good operational execution accompanied by continued significant financial growth for ViroPharma.
"While we clearly have much more to accomplish, including completing the tasks required for the approval of industrial scale manufacturing for Cinryze, we’ve made strides in the commercial growth of the product and have taken strong positive steps on the clinical side with both Cinryze and VP20621," Milano said.